

William M Pardridge

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3671308/william-m-pardridge-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

389
papers

27,233
citations

88
h-index

150
g-index

410
ext. papers

29,709
ext. citations

6.1
avg, IF

7.87
L-index

#	Paper	IF	Citations
389	Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins.. <i>Advanced Drug Delivery Reviews</i> , 2022 , 184, 114234	18.5	2
388	Mathematical Models of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Transferrin Receptor and the Insulin Receptor. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	8
387	Kinetics of Blood-Brain Barrier Transport of Monoclonal Antibodies Targeting the Insulin Receptor and the Transferrin Receptor.. <i>Pharmaceuticals</i> , 2021 , 15,	5.2	1
386	The Isolated Brain Microvessel: A Versatile Experimental Model of the Blood-Brain Barrier. <i>Frontiers in Physiology</i> , 2020 , 11, 398	4.6	20
385	Eliminating Fc N-Linked Glycosylation and Its Impact on Dosing Consideration for a Transferrin Receptor Antibody-Erythropoietin Fusion Protein in Mice. <i>Molecular Pharmaceutics</i> , 2020 , 17, 2831-2839	5.6	4
384	Lyoprotectant Optimization for the Freeze-Drying of Receptor-Targeted Trojan Horse Liposomes for Plasmid DNA Delivery. <i>Molecular Pharmaceutics</i> , 2020 , 17, 2165-2174	5.6	5
383	Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain.. <i>Frontiers in Medical Technology</i> , 2020 , 2, 602236	1.9	7
382	Treatment of Alzheimer's Disease and Blood-Brain Barrier Drug Delivery. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	29
381	Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes. <i>Scientific Reports</i> , 2020 , 10, 13334	4.9	9
380	Acute and Chronic Dosing of a High-Affinity Rat/Mouse Chimeric Transferrin Receptor Antibody in Mice. <i>Pharmaceutics</i> , 2020 , 12,	6.4	5
379	Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice. <i>Molecular Pharmaceutics</i> , 2019 , 16, 3534-3543	5.6	14
378	Preclinical studies of a brain penetrating IgG Trojan horse-arylsulfatase fusion protein in the metachromatic leukodystrophy mouse. <i>Molecular Genetics and Metabolism</i> , 2019 , 126, S77	3.7	4
377	Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain. <i>Frontiers in Aging Neuroscience</i> , 2019 , 11, 373	5.3	91
376	Hematologic safety of chronic brain-penetrating erythropoietin dosing in APP/PS1 mice. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 627-636	6	9
375	Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery. <i>Scientific Reports</i> , 2019 , 9, 18632	4.9	9
374	Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I. <i>BioDrugs</i> , 2018 , 32, 169-176	7.9	20
373	Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse. <i>Molecular Pharmaceutics</i> , 2018 , 15, 602-608	5.6	21

372	Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 110	4.2	61
371	P3-057: THERAPEUTIC EFFECTS OF A BRAIN PENETRATING BISPECIFIC ERYTHROPOIETIN-TRANSFERRIN RECEPTOR ANTIBODY FUSION PROTEIN IN THE APP/PS1 MOUSE MODEL OF ALZHEIMER'S DISEASE 2018, 14, P1086-P1087		1
370	Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease. <i>Molecular Pharmaceutics</i> , 2018, 15, 4963-4973	5.6	24
369	Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor. <i>Molecular Pharmaceutics</i> , 2018, 15, 5207-5216	5.6	31
368	Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein. <i>Molecular Pharmaceutics</i> , 2017, 14, 1271-1277	5.6	43
367	Blood-Brain Barrier Penetrating Biologic TNF-Inhibitor for Alzheimer's Disease. <i>Molecular Pharmaceutics</i> , 2017, 14, 2340-2349	5.6	51
366	Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology. <i>BioDrugs</i> , 2017, 31, 503-519	7.9	85
365	[O40604]: PROTECTIVE EFFECTS OF A BRAIN-PENETRATING BIOLOGIC TNF-ALPHA INHIBITOR IN A MOUSE MODEL OF ALZHEIMER'S DISEASE 2017, 13, P1242-P1242		
364	Non-invasive gene targeting to the fetal brain after intravenous administration and transplacental transfer of plasmid DNA using PEGylated immunoliposomes. <i>Journal of Drug Targeting</i> , 2016, 24, 58-67	5.4	10
363	Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1455-1468	5.4	41
362	Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey. <i>Molecular Pharmaceutics</i> , 2016, 13, 3241-6	5.6	13
361	Insulin Receptor Antibody-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosaminoglycans in Sanfilippo Type B Fibroblasts. <i>Molecular Pharmaceutics</i> , 2016, 13, 1385-92	5.6	25
360	CSF, blood-brain barrier, and brain drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 963-75	8	214
359	Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 207-22	8	98
358	S1-01-01: Blood-brain barrier from physiology to therapeutics 2015, 11, P114-P114		
357	Transport of Protein and Antibody Therapeutics Across the BloodBrain Barrier 2015, 146-166		
356	Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1059-72	6.4	83
355	Targeted delivery of protein and gene medicines through the blood-brain barrier. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 347-61	6.1	83

354	Blood-Brain Barrier Targeting of Therapeutic Lysosomal Enzymes. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2015 , 41-62	0.5	
353	Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys. <i>Biotechnology and Bioengineering</i> , 2014 , 111, 2317-25	4.9	66
352	Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosaminoglycans in Sanfilippo type A cells. <i>Molecular Pharmaceutics</i> , 2014 , 11, 2928-34	5.6	44
351	IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys. <i>Bioconjugate Chemistry</i> , 2013 , 24, 97-104	6.3	27
350	Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. <i>Bioconjugate Chemistry</i> , 2013 , 24, 1741-9	6.3	49
349	Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins. <i>Brain Research</i> , 2013 , 1507, 91-6	3.7	23
348	Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. <i>Biotechnology and Bioengineering</i> , 2013 , 110, 1456-65	4.9	44
347	Disaggregation of amyloid plaque in brain of Alzheimer's disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Aβ amyloid peptide. <i>Molecular Pharmaceutics</i> , 2013 , 10, 3507-13	5.6	38
346	Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice. <i>Molecular Pharmaceutics</i> , 2013 , 10, 1425-31	5.6	31
345	Imaging amyloid plaque in Alzheimer's disease brain with a biotinylated Aβ peptide radiopharmaceutical conjugated to an IgG-avidin fusion protein. <i>Bioconjugate Chemistry</i> , 2012 , 23, 1318-27	6.3	11
344	Drug transport across the blood-brain barrier. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012 , 32, 1959-72	7.3	942
343	Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. <i>Methods in Enzymology</i> , 2012 , 503, 269-92	1.7	139
342	Brain protection from stroke with intravenous TNF decoy receptor-Trojan horse fusion protein. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012 , 32, 1933-8	7.3	67
341	Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 329-35	4	34
340	Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies. <i>Journal of Drug Targeting</i> , 2012 , 20, 715-9	5.4	22
339	Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. <i>Drug Metabolism and Disposition</i> , 2012 , 40, 2021-5	4	39
338	Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein. <i>Brain Research</i> , 2011 , 1369, 203-7	3.7	24
337	Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse. <i>Brain Research</i> , 2011 , 1382, 315-20	3.7	28

336	CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG-paroxonase-1 fusion protein. <i>Biotechnology and Bioengineering</i> , 2011 , 108, 186-96	4.9	16
335	Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. <i>Biotechnology and Bioengineering</i> , 2011 , 108, 1954-64	4.9	30
334	Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain. <i>Molecular Pharmaceutics</i> , 2011 , 8, 280-5	5.6	33
333	Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. <i>Bioconjugate Chemistry</i> , 2011 , 22, 1611-8	6.3	21
332	Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. <i>Molecular Pharmaceutics</i> , 2011 , 8, 1342-50	5.6	54
331	Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011 , 339, 618-23	4.7	50
330	The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier. <i>Journal of Drug Delivery</i> , 2011 , 2011, 296151	2.3	53
329	Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 1149-54	4	34
328	Brain-penetrating tumor necrosis factor decoy receptor in the mouse. <i>Drug Metabolism and Disposition</i> , 2011 , 39, 71-6	4	30
327	Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse. <i>Drug Metabolism and Disposition</i> , 2010 , 38, 566-72	4	34
326	Biologic TNF inhibitors that cross the human blood-brain barrier. <i>Bioengineered Bugs</i> , 2010 , 1, 231-4		20
325	Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase. <i>Bioconjugate Chemistry</i> , 2010 , 21, 151-6	6.3	31
324	Biopharmaceutical drug targeting to the brain. <i>Journal of Drug Targeting</i> , 2010 , 18, 157-67	5.4	140
323	Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. <i>Molecular Pharmaceutics</i> , 2010 , 7, 237-44	5.6	73
322	Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. <i>Molecular Pharmaceutics</i> , 2010 , 7, 2148-55	5.6	28
321	Preparation of Trojan horse liposomes (THLs) for gene transfer across the blood-brain barrier. <i>Cold Spring Harbor Protocols</i> , 2010 , 2010, pdb.prot5407	1.2	27
320	Genetic engineering of IgG-glucuronidase fusion proteins. <i>Journal of Drug Targeting</i> , 2010 , 18, 205-11	5.4	28
319	Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010 , 333, 961-9	4.7	64

318	Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. <i>Brain Research</i> , 2010 , 1352, 208-13	3.7	46
317	Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein. <i>Brain Research</i> , 2010 , 1360, 193-7	3.7	17
316	IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey. <i>Biotechnology and Bioengineering</i> , 2010 , 105, 627-35	4.9	31
315	Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. <i>Journal of Biotechnology</i> , 2010 , 146, 84-91	3.7	68
314	Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 2299-304	4	55
313	Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. <i>Biotechnology and Bioengineering</i> , 2009 , 102, 1251-8	4.9	98
312	Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy. <i>Pharmaceutical Research</i> , 2009 , 26, 1059-63	4.5	49
311	Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. <i>Pharmaceutical Research</i> , 2009 , 26, 2227-36	4.5	38
310	AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. <i>Journal of Biotechnology</i> , 2009 , 144, 135-41	3.7	44
309	Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier. <i>Molecular Pharmaceutics</i> , 2009 , 6, 1536-43	5.6	23
308	Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. <i>Molecular Pharmaceutics</i> , 2009 , 6, 747-51	5.6	52
307	Alzheimer's disease drug development and the problem of the blood-brain barrier. <i>Alzheimer's and Dementia</i> , 2009 , 5, 427-32	1.2	123
306	Blood-Brain Barrier Transport for RNAi 2009 , 255-273		1
305	Blood-brain barrier genomics and cloning of a novel organic anion transporter. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008 , 28, 291-301	7.3	30
304	Strategies to advance translational research into brain barriers. <i>Lancet Neurology</i> , 2008 , 7, 84-96	24.1	370
303	Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. <i>Bioconjugate Chemistry</i> , 2008 , 19, 1327-38	6.3	135
302	Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. <i>Bioconjugate Chemistry</i> , 2008 , 19, 731-9	6.3	30
301	IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier. <i>Molecular Pharmaceutics</i> , 2008 , 5, 1037-43	5.6	20

300	Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer. <i>Pharmaceutical Research</i> , 2008 , 25, 400-6	4.5	40
299	Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. <i>Journal of Gene Medicine</i> , 2008 , 10, 306-15	3.5	72
298	Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. <i>Biotechnology and Bioengineering</i> , 2008 , 99, 475-84	4.9	113
297	GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier. <i>Biotechnology and Bioengineering</i> , 2008 , 100, 387-96	4.9	76
296	Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. <i>Bioconjugate Chemistry</i> , 2007 , 18, 447-55	6.3	101
295	Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. <i>Biotechnology and Bioengineering</i> , 2007 , 96, 381-91	4.9	155
294	Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. <i>Biotechnology and Bioengineering</i> , 2007 , 97, 1376-86	4.9	68
293	Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes. <i>Journal of Gene Medicine</i> , 2007 , 9, 605-12	3.5	16
292	Blood-brain barrier delivery. <i>Drug Discovery Today</i> , 2007 , 12, 54-61	8.8	840
291	Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. <i>Journal of Controlled Release</i> , 2007 , 122, 345-8	11.7	69
290	shRNA and siRNA delivery to the brain. <i>Advanced Drug Delivery Reviews</i> , 2007 , 59, 141-52	18.5	149
289	Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. <i>Pharmaceutical Research</i> , 2007 , 24, 2309-16	4.5	106
288	Blood-brain barrier genomics. <i>Stroke</i> , 2007 , 38, 686-90	6.7	37
287	Drug targeting to the brain. <i>Pharmaceutical Research</i> , 2007 , 24, 1733-44	4.5	349
286	Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. <i>Brain Research</i> , 2006 , 1111, 227-9	3.7	128
285	Imaging Gene Expression in the Brain with Peptide Nucleic Acid (PNA) Antisense Radiopharmaceuticals and Drug Targeting Technology 2006 , 38-60		1
284	Molecular Trojan horses for blood-brain barrier drug delivery. <i>Current Opinion in Pharmacology</i> , 2006 , 6, 494-500	5.1	173
283	Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation. <i>Pharmaceutical Research</i> , 2006 , 23, 1586-90	4.5	18

282	Molecular Trojan horses for blood-brain barrier drug delivery. <i>Discovery Medicine</i> , 2006 , 6, 139-43	2.5	40
281	Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems. <i>International Congress Series</i> , 2005 , 1277, 49-62		38
280	Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2005 , 1715, 104-10	3.8	25
279	Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. <i>NeuroRx</i> , 2005 , 2, 129-38		75
278	The blood-brain barrier: bottleneck in brain drug development. <i>NeuroRx</i> , 2005 , 2, 3-14		1669
277	Molecular biology of the blood-brain barrier. <i>Molecular Biotechnology</i> , 2005 , 30, 57-70	3	138
276	Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 313, 1075-81	4.7	96
275	Imaging gene expression in the brain with peptide nucleic acid (PNA) antisense radiopharmaceuticals and drug targeting technology. <i>International Journal of Peptide Research and Therapeutics</i> , 2005 , 10, 169-190	2.1	
274	Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. <i>Neurotherapeutics</i> , 2005 , 2, 129-138	6.4	
273	The blood-brain barrier: Bottleneck in brain drug development 2005 , 2, 3		6
272	Imaging Gene Expression in Regional Brain Ischemia in Vivo with a Targeted [111In]-Antisense Radiopharmaceutical. <i>Molecular Imaging</i> , 2004 , 3, 153535002004041	3.7	
271	Developmental regulation of the rabbit blood-brain barrier LAT1 large neutral amino acid transporter mRNA and protein. <i>Pediatric Research</i> , 2004 , 55, 557-60	3.2	10
270	Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 3667-77	12.9	286
269	Log(BB), PS products and in silico models of drug brain penetration. <i>Drug Discovery Today</i> , 2004 , 9, 392-38.8		79
268	Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. <i>Journal of Gene Medicine</i> , 2004 , 6, 906-12	3.5	26
267	Gene therapy of the brain: the trans-vascular approach. <i>Neurology</i> , 2004 , 62, 1275-81	6.5	77
266	Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. <i>Human Gene Therapy</i> , 2004 , 15, 339-50	4.8	106
265	Intravenous, non-viral RNAi gene therapy of brain cancer. <i>Expert Opinion on Biological Therapy</i> , 2004 , 4, 1103-13	5.4	99

264	Human LAT1 single nucleotide polymorphism N230K does not alter phenylalanine transport. <i>Molecular Genetics and Metabolism</i> , 2004 , 83, 306-11	3.7	12
263	Imaging gene expression in regional brain ischemia in vivo with a targeted [¹¹¹ In]-antisense radiopharmaceutical. <i>Molecular Imaging</i> , 2004 , 3, 356-63	3.7	12
262	Imaging endogenous gene expression in brain cancer in vivo with ¹¹¹ In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. <i>Journal of Nuclear Medicine</i> , 2004 , 45, 1766-75	8.9	45
261	Global non-viral gene transfer to the primate brain following intravenous administration. <i>Molecular Therapy</i> , 2003 , 7, 11-8	11.7	148
260	Molecular biology of the blood-brain barrier. <i>Methods in Molecular Medicine</i> , 2003 , 89, 385-99		20
259	P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain. <i>NeuroReport</i> , 2003 , 14, 2041-6	1.7	51
258	The Ro52/SS-A autoantigen has elevated expression at the brain microvasculature. <i>NeuroReport</i> , 2003 , 14, 1861-5	1.7	18
257	Blood-brain barrier drug targeting: the future of brain drug development. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2003 , 3, 90-105, 51		501
256	Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. <i>Pharmaceutical Research</i> , 2003 , 20, 1779-85	4.5	49
255	Marked enhancement in gene expression by targeting the human insulin receptor. <i>Journal of Gene Medicine</i> , 2003 , 5, 157-63	3.5	41
254	In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. <i>Journal of Gene Medicine</i> , 2003 , 5, 1039-45	3.5	105
253	Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234. <i>Journal of Neurochemistry</i> , 2003 , 84, 1322-31	6	20
252	Hypoxia induces de-stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells. <i>Journal of Neurochemistry</i> , 2003 , 85, 1037-42	6	23
251	Gene targeting in vivo with pegylated immunoliposomes. <i>Methods in Enzymology</i> , 2003 , 373, 507-28	1.7	42
250	Monoclonal antibody radiopharmaceuticals: cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging. <i>Bioconjugate Chemistry</i> , 2003 , 14, 546-53	6.3	66
249	Imaging gene expression in the brain with peptide nucleic acid (PNA) antisense radiopharmaceuticals and drug targeting technology. <i>International Journal of Peptide Research and Therapeutics</i> , 2003 , 10, 169-190	2.1	1
248	Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. <i>Human Gene Therapy</i> , 2003 , 14, 1-12	4.8	176
247	Imaging gene expression in the brain with peptide nucleic acid (PNA) antisense radiopharmaceuticals and drug targeting technology. <i>International Journal of Peptide Research and Therapeutics</i> , 2003 , 10, 169-190		

246	Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. <i>Molecular Vision</i> , 2003 , 9, 465-72	2.3	66
245	Blood-brain barrier genomics and the use of endogenous transporters to cause drug penetration into the brain. <i>Current Opinion in Drug Discovery & Development</i> , 2003 , 6, 683-91		12
244	Formulation of therapeutic synthetic polymers for drug and gene delivery. <i>Drug Discovery Today</i> , 2002 , 7, 1120-1	8.8	2
243	Receptor-mediated delivery of an antisense gene to human brain cancer cells. <i>Journal of Gene Medicine</i> , 2002 , 4, 183-94	3.5	109
242	Glucose deprivation and hypoxia increase the expression of the GLUT1 glucose transporter via a specific mRNA cis-acting regulatory element. <i>Journal of Neurochemistry</i> , 2002 , 80, 552-4	6	62
241	Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. <i>Journal of Neurochemistry</i> , 2002 , 81, 203-6	6	193
240	Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002 , 22, 223-31	7.3	65
239	Vascular genomics of the human brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002 , 22, 245-52	7.3	47
238	Rat blood-brain barrier genomics. II. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002 , 22, 1319-26	7.3	29
237	Drug and gene targeting to the brain with molecular Trojan horses. <i>Nature Reviews Drug Discovery</i> , 2002 , 1, 131-9	64.1	349
236	Synthesis of pegylated immunonanoparticles. <i>Pharmaceutical Research</i> , 2002 , 19, 1137-43	4.5	178
235	Blood-brain barrier disruption following the internal carotid arterial perfusion of alkyl glycerols. <i>Journal of Drug Targeting</i> , 2002 , 10, 463-7	5.4	27
234	Vascular proteomics and subtractive antibody expression cloning. <i>Molecular and Cellular Proteomics</i> , 2002 , 1, 75-82	7.6	23
233	Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 301, 605-10	4.7	114
232	Targeting neurotherapeutic agents through the blood-brain barrier. <i>Archives of Neurology</i> , 2002 , 59, 35-40		86
231	Subtractive expression cloning reveals high expression of CD46 at the blood-brain barrier. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002 , 61, 597-604	3.1	45
230	Antisense gene therapy of brain cancer with an artificial virus gene delivery system. <i>Molecular Therapy</i> , 2002 , 6, 67-72	11.7	131
229	Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. <i>Journal of Drug Targeting</i> , 2002 , 10, 239-45	5.4	49

228	Drug and gene delivery to the brain: the vascular route. <i>Neuron</i> , 2002 , 36, 555-8	13.9	329
227	Rat Blood-Brain Barrier Genomics. II. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002 , 1319-1326	7.3	13
226	Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. <i>Advances in Experimental Medicine and Biology</i> , 2002 , 513, 397-430	3.6	49
225	Imaging gene expression in the brain in vivo in a transgenic mouse model of Huntington's disease with an antisense radiopharmaceutical and drug-targeting technology. <i>Journal of Nuclear Medicine</i> , 2002 , 43, 948-56	8.9	43
224	Widespread expression of an exogenous gene in the eye after intravenous administration. <i>Investigative Ophthalmology and Visual Science</i> , 2002 , 43, 3075-80		25
223	Neurotrophins, neuroprotection and the blood-brain barrier. <i>Current Opinion in Investigational Drugs</i> , 2002 , 3, 1753-7		31
222	Brain drug targeting and gene technologies. <i>The Japanese Journal of Pharmacology</i> , 2001 , 87, 97-103		43
221	Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. <i>Stroke</i> , 2001 , 32, 1378-84	6.7	152
220	Rapid transferrin efflux from brain to blood across the blood-brain barrier. <i>Journal of Neurochemistry</i> , 2001 , 76, 1597-600	6	109
219	Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. <i>Pharmaceutical Research</i> , 2001 , 18, 1091-5	4.5	119
218	Blood-brain barrier genomics. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001 , 21, 61-8	7.3	135
217	Cloned blood-brain barrier adenosine transporter is identical to the rat concentrative Na ⁺ nucleoside cotransporter CNT2. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001 , 21, 929-36	7.3	64
216	Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. <i>Journal of Neuroimmunology</i> , 2001 , 114, 168-72	3.5	192
215	Delivery of peptides and proteins through the blood-brain barrier. <i>Advanced Drug Delivery Reviews</i> , 2001 , 46, 247-79	18.5	348
214	Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. <i>Brain Research</i> , 2001 , 889, 49-56	3.7	142
213	Crossing the blood-brain barrier: are we getting it right?. <i>Drug Discovery Today</i> , 2001 , 6, 1-2	8.8	63
212	BBB-Genomics: creating new openings for brain-drug targeting. <i>Drug Discovery Today</i> , 2001 , 6, 381-383	8.8	59
211	Neuroprotection in stroke: is it time to consider large-molecule drugs?. <i>Drug Discovery Today</i> , 2001 , 6, 751-753	8.8	2

210	Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. <i>Bioconjugate Chemistry</i> , 2001 , 12, 995-9	6.3	73
209	Brain Drug Targeting: The Future of Brain Drug Development 2001 ,		91
208	Selective Lutheran glycoprotein gene expression at the blood-brain barrier in normal brain and in human brain tumors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000 , 20, 1096-102	7.3	15
207	Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain. <i>Cellular and Molecular Neurobiology</i> , 2000 , 20, 165-81	4.6	59
206	Blood-brain barrier transport of 125I-labeled basic fibroblast growth factor. <i>Pharmaceutical Research</i> , 2000 , 17, 63-9	4.5	55
205	Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. <i>Pharmaceutical Research</i> , 2000 , 17, 266-74	4.5	151
204	Aβ(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. <i>Bioconjugate Chemistry</i> , 2000 , 11, 380-6	6.3	45
203	Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease). <i>Journal of Drug Targeting</i> , 2000 , 8, 413-24	5.4	15
202	Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. <i>Bioconjugate Chemistry</i> , 1999 , 10, 502-11	6.3	58
201	Blood-brain barrier biology and methodology. <i>Journal of NeuroVirology</i> , 1999 , 5, 556-69	3.9	342
200	Blood-brain barrier transport of reduced folic acid. <i>Pharmaceutical Research</i> , 1999 , 16, 415-9	4.5	65
199	Vector-mediated drug delivery to the brain. <i>Advanced Drug Delivery Reviews</i> , 1999 , 36, 299-321	18.5	114
198	P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. <i>Brain Research</i> , 1999 , 819, 143-6	3.7	89
197	Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. <i>Pharmaceutical Science & Technology Today</i> , 1999 , 2, 49-59		54
196	Amplification of gene expression using both 5'- and 3'-untranslated regions of GLUT1 glucose transporter mRNA. <i>Molecular Brain Research</i> , 1999 , 63, 371-4		8
195	Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. <i>Bioconjugate Chemistry</i> , 1999 , 10, 32-7	6.3	39
194	hnRNP A2 and hnRNP L bind the 3'UTR of glucose transporter 1 mRNA and exist as a complex in vivo. <i>Biochemical and Biophysical Research Communications</i> , 1999 , 261, 646-51	3.4	78
193	Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. <i>Pharmaceutical Research</i> , 1998 , 15, 576-82	4.5	108

192	Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. <i>Neurochemical Research</i> , 1998 , 23, 635-44	4.6	191
191	Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS. <i>Journal of Pharmaceutical Sciences</i> , 1998 , 87, 1308-15	3.9	52
190	Low blood-brain barrier permeability to azidothymidine (AZT), 3TC, and thymidine in the rat. <i>Brain Research</i> , 1998 , 791, 313-6	3.7	42
189	GLUT1 glucose transporter: differential gene transcription and mRNA binding to cytosolic and polysome proteins in brain and peripheral tissues. <i>Molecular Brain Research</i> , 1998 , 58, 170-7		19
188	Ten nucleotide cis element in the 3'-untranslated region of the GLUT1 glucose transporter mRNA increases gene expression via mRNA stabilization. <i>Molecular Brain Research</i> , 1998 , 59, 109-13		50
187	Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. <i>Journal of Neurochemistry</i> , 1998 , 70, 883-6	6	53
186	CNS drug design based on principles of blood-brain barrier transport. <i>Journal of Neurochemistry</i> , 1998 , 70, 1781-92	6	315
185	Up-regulation of blood-brain barrier short-form leptin receptor gene products in rats fed a high fat diet. <i>Journal of Neurochemistry</i> , 1998 , 71, 1761-4	6	64
184	Treatment of large solid tumors in mice with daunomycin-loaded sterically stabilized liposomes. <i>Drug Delivery</i> , 1998 , 5, 207-12	7	8
183	Drug transport across the bloodBrain barrier: In Vitro and In Vivo techniques. <i>Drug Delivery</i> , 1998 , 5, 153-153	7	1
182	Targeted Delivery of Hormones to Tissues by Plasma Proteins 1998 , 335-382		3
181	Interactions of lipoproteins with the bloodBrain barrier 1998 , 221-226		0
180	Tissue culture of brain endothelial cells Induction of bloodBrain barrier properties by brain factors 1998 , 79-85		4
179	BloodBrain barrier ion transport 1998 , 207-213		5
178	BloodBrain barrier amino acid transport 1998 , 188-197		28
177	Transport in the developing brain 1998 , 277-290		5
176	The carotid artery single injection technique 1998 , 11-23		3
175	Development of Brain Efflux Index (BEI) method and its application to the bloodBrain barrier efflux transport study 1998 , 24-31		3

174	Isolation and behavior of plasma membrane vesicles made from cerebral capillary endothelial cells 1998, 62-70	4
173	Isolated brain capillaries: an in vitro model of blood-brain barrier research 1998, 49-61	11
172	Cytokines and the blood-brain barrier 1998, 354-361	1
171	In situ brain perfusion 1998, 32-40	1
170	HIV infection and the blood-brain barrier 1998, 419-426	3
169	Blood-brain barrier and monoamines, revisited 1998, 362-376	2
168	Brain microvessel endothelial cell culture systems 1998, 86-93	8
167	Role of intracellular calcium in regulation of brain endothelial permeability 1998, 345-353	9
166	Blood-brain barrier methodology and biology 1998, 1-8	10
165	Patch clamp techniques with isolated brain microvessel membranes 1998, 71-78	2
164	Intracerebral microdialysis 1998, 94-112	5
163	Blood-brain barrier permeability measured with histochemistry 1998, 113-121	6
162	Measuring cerebral capillary permeability-surface area products by quantitative autoradiography 1998, 122-132	3
161	Measurement of blood-brain barrier in humans using indicator diffusion 1998, 133-139	2
160	Measurement of blood-brain permeability in humans with positron emission tomography 1998, 140-146	1
159	Molecular biology of brain capillaries 1998, 151-162	4
158	Biology of the blood-brain glucose transporter 1998, 165-174	9
157	Glucose transporters in mammalian brain development 1998, 175-187	1

156	P-glycoprotein, a guardian of the brain 1998 , 198-206	4
155	Ion channels in endothelial cells 1998 , 214-220	2
154	BloodBrain barrier transport of drugs 1998 , 238-248	7
153	The blood-CSF barrier and the choroid plexus 1998 , 251-258	7
152	Arachnoid membrane, subarachnoid CSF and pia glia 1998 , 259-269	4
151	Circumventricular organs of the brain 1998 , 270-276	6
150	Regulation of brain endothelial cell tight junction permeability 1998 , 293-300	2
149	Chemotherapy and chemosensitization 1998 , 301-307	1
148	Molecular dissection of tight junctions: occludin and ZO-1 1998 , 322-329	5
147	Nitric oxide and endothelin at the bloodBrain barrier 1998 , 338-344	0
146	Cerebral amyloid angiopathy 1998 , 379-385	4
145	Brain microvasculature in multiple sclerosis 1998 , 386-400	8
144	Hemostasis and the bloodBrain barrier 1998 , 401-408	1
143	Microvascular pathology in cerebrovascular ischemia 1998 , 409-418	2
142	The blood-brain barrier in brain tumours 1998 , 434-440	3
141	The pathophysiology of bloodBrain barrier dysfunction due to traumatic brain injury 1998 , 441-453	5
140	Lipid composition of brain microvessels 1998 , 308-313	
139	Magnetic resonance imaging of bloodBrain barrier permeability 1998 , 147-150	

138 Intravenous injection/pharmacokinetics **1998**, 41-48

137 Brain microvessel antigens **1998**, 314-321

136 Fatty acid and lipid intermediate transport **1998**, 227-237

135 Phosphatidylinositol pathways **1998**, 330-337

134 The 5'-untranslated region of GLUT1 glucose transporter mRNA causes differential regulation of the translational rate in plant and animal systems. *Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology*, **1997**, 118, 309-12 2.3 6

133 Drug delivery to the brain. *Journal of Cerebral Blood Flow and Metabolism*, **1997**, 17, 713-31 7.3 221

132 Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. *Pharmaceutical Research*, **1997**, 14, 1085-91 4.5 89

131 Brain microvascular and astrocyte localization of P-glycoprotein. *Journal of Neurochemistry*, **1997**, 68, 1278-85 6 107

130 Site-directed deletion of a 10-nucleotide domain of the 3'-untranslated region of the GLUT1 glucose transporter mRNA eliminates cytosolic protein binding in human brain tumors and induction of reporter gene expression. *Journal of Neurochemistry*, **1997**, 68, 2587-92 6 13

129 Blood-Brain Barrier Transport Mechanisms **1997**, 21-25 2

128 Cis-element/cytoplasmic protein interaction within the 3'-untranslated region of the GLUT1 glucose transporter mRNA. *Journal of Neurochemistry*, **1996**, 66, 449-58 6 37

127 Evidence for translational control elements within the 5'-untranslated region of GLUT1 glucose transporter mRNA. *Journal of Neurochemistry*, **1996**, 67, 1335-43 6 24

126 Physiologic-based strategies for protein drug delivery to the brain. *Journal of Controlled Release*, **1996**, 39, 281-286 11.7 7

125 Pathological upregulation of inner blood-retinal barrier Glut1 glucose transporter expression in diabetes mellitus. *Brain Research*, **1996**, 706, 313-7 3.7 60

124 Brain drug delivery and blood-brain barrier transport. *Drug Delivery*, **1996**, 3, 99-115 7 24

123 Transport of small molecules through the blood-brain barrier: biology and methodology. *Advanced Drug Delivery Reviews*, **1995**, 15, 5-36 18.5 211

122 Vector-mediated peptide drug delivery to the brain. *Advanced Drug Delivery Reviews*, **1995**, 15, 109-146 18.5 37

121 Transport of [125I]transferrin through the rat blood-brain barrier. *Brain Research*, **1995**, 683, 164-71 3.7 141

120	Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. <i>Pharmaceutical Research</i> , 1995 , 12, 807-16	4.5	226
119	Targeting of an anti-CD11b/CD18 monoclonal antibody to spleen but not brain, in vivo in mice. <i>Journal of Drug Targeting</i> , 1995 , 3, 9-14	5.4	9
118	Pharmacokinetics of [3H]biotin bound to different avidin analogues. <i>Journal of Drug Targeting</i> , 1995 , 3, 159-65	5.4	37
117	Pharmacokinetic differences between 111In- and 125I-labeled cationized monoclonal antibody against β -Amyloid in mouse and dog. <i>Drug Delivery</i> , 1995 , 2, 128-135	7	11
116	In vivo cleavability of a disulfide-based chimeric opioid peptide in rat brain. <i>Bioconjugate Chemistry</i> , 1995 , 6, 211-8	6.3	41
115	Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization. <i>Journal of Pharmaceutical Sciences</i> , 1995 , 84, 943-8	3.9	43
114	Molecular Regulation of Blood-Brain Barrier GLUT1 Glucose Transporter 1995 , 81-88		1
113	Vector-mediated peptide drug delivery to the brain.. <i>Advanced Drug Delivery Reviews</i> , 1995 , 15, 109-146	18.5	
112	Transport of small molecules through the blood-brain barrier: biology and methodology.. <i>Advanced Drug Delivery Reviews</i> , 1995 , 15, 5-36	18.5	
111	Measurement of blood-brain barrier GLUT1 glucose transporter and actin mRNA by a quantitative polymerase chain reaction assay. <i>Journal of Neurochemistry</i> , 1994 , 62, 2085-90	6	29
110	Cationization of a monoclonal antibody to the human immunodeficiency virus REV protein enhances cellular uptake but does not impair antigen binding of the antibody. <i>Immunology Letters</i> , 1994 , 42, 191-5	4.1	28
109	New approaches to drug delivery through the blood-brain barrier. <i>Trends in Biotechnology</i> , 1994 , 12, 239-45	15.1	29
108	Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. <i>Pharmaceutical Research</i> , 1994 , 11, 738-46	4.5	154
107	Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin. <i>Pharmaceutical Research</i> , 1994 , 11, 1257-64	4.5	36
106	Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. <i>Molecular Brain Research</i> , 1994 , 27, 51-7		117
105	Enhanced expression of the blood-brain barrier GLUT1 glucose transporter gene by brain-derived factors. <i>Molecular Brain Research</i> , 1994 , 22, 259-67		42
104	Differential glycosylation of the GLUT1 glucose transporter in brain capillaries and choroid plexus. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1994 , 1193, 24-30	3.8	45
103	Complete inactivation of target mRNA by biotinylated antisense oligodeoxynucleotide-avidin conjugates. <i>Bioconjugate Chemistry</i> , 1994 , 5, 406-10	6.3	28

102	Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: a potential probe for Alzheimer's disease. <i>Bioconjugate Chemistry</i> , 1994 , 5, 119-25	6.3	24
101	Enzymatic barrier protects brain capillaries from leukotriene C4. <i>Journal of Neurosurgery</i> , 1994 , 81, 745-51	5.12	29
100	Steroid Hormone Transport through Blood-Brain Barrier: Methods and Concepts. <i>Methods in Neurosciences</i> , 1994 , 22, 3-22		3
99	Transport of insulin-related peptides and glucose across the blood-brain barrier. <i>Annals of the New York Academy of Sciences</i> , 1993 , 692, 126-37	6.5	67
98	Drug delivery of antisense oligonucleotides or peptides to tissues in vivo using an avidin-biotin system. <i>Drug Delivery</i> , 1993 , 1, 43-50	7	17
97	Brain drug delivery and blood-brain barrier transport. <i>Drug Delivery</i> , 1993 , 1, 83-101	7	26
96	Localization of Blood-Brain Barrier-Specific Antibodies with Immunogold-Silver Enhancement. <i>Journal of Histotechnology</i> , 1993 , 16, 249-257	1.3	2
95	An electron microscopic immunogold analysis of developmental up-regulation of the blood-brain barrier GLUT1 glucose transporter. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993 , 13, 841-54	7.3	58
94	Glucose deprivation causes posttranscriptional enhancement of brain capillary endothelial glucose transporter gene expression via GLUT1 mRNA stabilization. <i>Journal of Neurochemistry</i> , 1993 , 60, 2290-6	6	113
93	Delivery of peptides and proteins through the blood-brain barrier. <i>Advanced Drug Delivery Reviews</i> , 1993 , 10, 205-245	18.5	35
92	Insulin therapy normalizes GLUT1 glucose transporter mRNA but not immunoreactive transporter protein in streptozocin-diabetic rats. <i>Metabolism: Clinical and Experimental</i> , 1993 , 42, 939-44	12.7	27
91	Enhanced GLUT1 glucose transporter and cytoskeleton gene expression in cultured bovine brain capillary endothelial cells after treatment with phorbol esters and serum. <i>Molecular Brain Research</i> , 1992 , 15, 221-6		18
90	Complete protection of antisense oligonucleotides against serum nuclease degradation by an avidin-biotin system. <i>Bioconjugate Chemistry</i> , 1992 , 3, 519-23	6.3	30
89	Determination of in vivo steady-state unbound drug concentration in the brain interstitial fluid by microdialysis. <i>International Journal of Pharmaceutics</i> , 1992 , 81, 143-152	6.5	42
88	Recent developments in peptide drug delivery to the brain. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1992 , 71, 3-10		46
87	Brain Capillary Endothelial Transport of Insulin 1992 , 347-362		2
86	Ultrastructural localization of blood-brain barrier-specific antibodies using immunogold-silver enhancement techniques. <i>Journal of Neuroscience Methods</i> , 1991 , 37, 103-10	3	12
85	A one-step procedure for isolation of poly(A) ⁺ mRNA from isolated brain capillaries and endothelial cells in culture. <i>Journal of Neurochemistry</i> , 1991 , 57, 2136-9	6	66

84	Enhanced cellular uptake of biotinylated antisense oligonucleotide or peptide mediated by avidin, a cationic protein. <i>FEBS Letters</i> , 1991 , 288, 30-2	3.8	63
83	Blood-brain barrier transport of glucose, free fatty acids, and ketone bodies. <i>Advances in Experimental Medicine and Biology</i> , 1991 , 291, 43-53	3.6	18
82	Astrocyte growth stimulation by a soluble factor produced by cerebral endothelial cells in vitro. <i>Journal of Neuropathology and Experimental Neurology</i> , 1990 , 49, 539-49	3.1	61
81	Transport of tryptophan into brain from the circulating, albumin-bound pool in rats and in rabbits. <i>Journal of Neurochemistry</i> , 1990 , 54, 971-6	6	62
80	Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. <i>Journal of Neurochemistry</i> , 1990 , 54, 1882-8	6	410
79	Measurement of free intracellular and transfer RNA amino acid specific activity and protein synthesis in rat brain in vivo. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1990 , 10, 162-9	7.3	20
78	Reduction of testosterone availability to 5 alpha-reductase by human sex hormone-binding globulin in the rat ventral prostate gland in vivo. <i>Prostate</i> , 1990 , 17, 281-91	4.2	10
77	Red cell phenylalanine is not available for transport through the blood-brain barrier. <i>Neurochemical Research</i> , 1990 , 15, 769-72	4.6	7
76	Immunohistochemical study of cerebral amyloid angiopathy. III. Widespread Alzheimer A4 peptide in cerebral microvessel walls colocalizes with gamma trace in patients with leukoencephalopathy. <i>Annals of Neurology</i> , 1990 , 28, 34-42	9.4	76
75	Beta-endorphin chimeric peptides: transport through the blood-brain barrier in vivo and cleavage of disulfide linkage by brain. <i>Endocrinology</i> , 1990 , 126, 977-84	4.8	61
74	Molecular cloning of the bovine blood-brain barrier glucose transporter cDNA and demonstration of phylogenetic conservation of the 5'-untranslated region. <i>Molecular and Cellular Neurosciences</i> , 1990 , 1, 224-32	4.8	66
73	Differential expression of 53- and 45-kDa brain capillary-specific proteins by brain capillary endothelium and choroid plexus in vivo and by brain capillary endothelium in tissue culture. <i>Molecular and Cellular Neurosciences</i> , 1990 , 1, 20-8	4.8	16
72	Kinetics of lactate transport into rat liver in vivo. <i>Metabolism: Clinical and Experimental</i> , 1990 , 39, 374-7	12.7	13
71	Decreases in brain protein synthesis elicited by moderate increases in plasma phenylalanine. <i>Biochemical and Biophysical Research Communications</i> , 1990 , 168, 1177-83	3.4	12
70	The brain-type glucose transporter mRNA is specifically expressed at the blood-brain barrier. <i>Biochemical and Biophysical Research Communications</i> , 1990 , 166, 174-9	3.4	102
69	Triiodothyronine bound to red blood cells is not available for transport through the blood-brain barrier. <i>Neurochemical Research</i> , 1989 , 14, 657-9	4.6	1
68	Predominant low-molecular-weight proteins in isolated brain capillaries are histones. <i>Journal of Neurochemistry</i> , 1989 , 53, 1014-8	6	2
67	Brain capillary 46,000 dalton protein is cytoplasmic actin and is localized to endothelial plasma membrane. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1989 , 9, 675-80	7.3	32

66	Strategies for drug delivery through the blood-brain barrier. <i>Neurobiology of Aging</i> , 1989 , 10, 636-7; discussion 648-50	5.6	13
65	Blood-brain barrier glucose transporter mRNA is increased in experimental diabetes mellitus. <i>Biochemical and Biophysical Research Communications</i> , 1989 , 164, 375-80	3.4	50
64	Influx of testosterone-binding globulin (TeBG) and TeBG-bound sex steroid hormones into rat testis and prostate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1988 , 67, 98-103	5.6	47
63	Human blood-brain barrier insulin-like growth factor receptor. <i>Metabolism: Clinical and Experimental</i> , 1988 , 37, 136-40	12.7	130
62	Immunohistochemical study of cerebral amyloid angiopathy: use of an antiserum to a synthetic 28-amino-acid peptide fragment of the Alzheimer's disease amyloid precursor. <i>Human Pathology</i> , 1988 , 19, 214-22	3.7	33
61	Selective delivery of sex steroid hormones to tissues in vivo by albumin and by sex hormone-binding globulin. <i>Annals of the New York Academy of Sciences</i> , 1988 , 538, 173-92	6.5	39
60	New directions in blood-brain barrier research. Studies with isolated human brain capillaries. <i>Annals of the New York Academy of Sciences</i> , 1988 , 529, 50-60	6.5	9
59	Developmental changes in brain and serum binding of testosterone and in brain capillary uptake of testosterone-binding serum proteins in the rabbit. <i>Developmental Brain Research</i> , 1988 , 466, 245-53		14
58	Does the brain's gatekeeper falter in aging?. <i>Neurobiology of Aging</i> , 1988 , 9, 44-6	5.6	17
57	Receptor-mediated peptide transport through the blood-brain barrier 1988 , 593-595		1
56	Phenylalanine Transport at the Human Blood-Brain Barrier 1988 , 55-62		5
55	Human blood-brain barrier transferrin receptor. <i>Metabolism: Clinical and Experimental</i> , 1987 , 36, 892-5	12.7	274
54	The effects of membrane permeability and binding by human serum proteins on steroid influx into the rabbit uterus. <i>American Journal of Obstetrics and Gynecology</i> , 1987 , 157, 1543-9	6.4	
53	Blood-brain barrier transcytosis of insulin in developing rabbits. <i>Brain Research</i> , 1987 , 420, 32-8	3.7	319
52	Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier. <i>Biochemical and Biophysical Research Communications</i> , 1987 , 146, 307-13	3.4	66
51	High molecular weight Alzheimer's disease amyloid peptide immunoreactivity in human serum and CSF is an immunoglobulin G. <i>Biochemical and Biophysical Research Communications</i> , 1987 , 145, 241-8	3.4	26
50	Amyloid angiopathy of Alzheimer's disease: amino acid composition and partial sequence of a 4,200-dalton peptide isolated from cortical microvessels. <i>Journal of Neurochemistry</i> , 1987 , 49, 1394-401	6	63
49	Blood-brain barrier transport of nutrients. <i>Nutrition Reviews</i> , 1986 , 44 Suppl, 15-25	6.4	37

48	Serum bioavailability and tissue metabolism of testosterone and estradiol in rat salivary gland. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986 , 63, 20-8	5.6	24
47	Antibodies to blood-brain barrier bind selectively to brain capillary endothelial lateral membranes and to a 46K protein. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1986 , 6, 203-11	7.3	48
46	Mechanisms of neuropeptide interaction with the blood-brain barrier. <i>Annals of the New York Academy of Sciences</i> , 1986 , 481, 231-49	6.5	22
45	Receptor-mediated peptide transport through the blood-brain barrier. <i>Endocrine Reviews</i> , 1986 , 7, 314-307.2	7.2	264
44	Serum bioavailability of sex steroid hormones. <i>Clinics in Endocrinology and Metabolism</i> , 1986 , 15, 259-78		157
43	Enhanced hepatic extraction of estrogens used for replacement therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986 , 62, 761-6	5.6	62
42	Blood-brain barrier: interface between internal medicine and the brain. <i>Annals of Internal Medicine</i> , 1986 , 105, 82-95	8	117
41	The blood-brain barrier in Alzheimer's disease. <i>Canadian Journal of Neurological Sciences</i> , 1986 , 13, 446-81		21
40	Blood-brain barrier protein phosphorylation and dephosphorylation. <i>Journal of Neurochemistry</i> , 1985 , 45, 1141-7	6	62
39	Human blood-brain barrier insulin receptor. <i>Journal of Neurochemistry</i> , 1985 , 44, 1771-8	6	317
38	Restricted transport of vitamin D and A derivatives through the rat blood-brain barrier. <i>Journal of Neurochemistry</i> , 1985 , 44, 1138-41	6	92
37	Rapid sequestration and degradation of somatostatin analogues by isolated brain microvessels. <i>Journal of Neurochemistry</i> , 1985 , 44, 1178-84	6	111
36	Blood-brain barrier transport of valproic acid. <i>Journal of Neurochemistry</i> , 1985 , 44, 1541-50	6	92
35	Restrictive transport of a lipid-soluble peptide (cyclosporin) through the blood-brain barrier. <i>Journal of Neurochemistry</i> , 1985 , 45, 1954-6	6	88
34	Kinetics of regional blood-brain barrier glucose transport and cerebral blood flow determined with the carotid injection technique in conscious rats. <i>Journal of Neurochemistry</i> , 1985 , 44, 911-5	6	43
33	Blood-brain barrier transport of butanol and water relative to N-isopropyl-p-iodoamphetamine as the internal reference. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1985 , 5, 275-81	7.3	77
32	Two-day starvation does not alter the kinetics of blood-brain barrier transport and phosphorylation of glucose in rat brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1985 , 5, 40-6	7.3	28
31	Carotid artery injection technique: bounds for bolus mixing by plasma and by brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1985 , 5, 576-83	7.3	59

30	Chapter 31. Strategies for Delivery of Drugs Through the Blood-Brain Barrier. <i>Annual Reports in Medicinal Chemistry</i> , 1985 , 20, 305-313	1.6	19
29	Strategies for Drug Delivery through the Blood-Brain Barrier 1985 , 83-96		14
28	Protein-bound corticosteroid in human serum is selectively transported into rat brain and liver in vivo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983 , 57, 160-5	5.6	36
27	The effect of membrane permeability and binding by human serum proteins on sex steroid influx into the uterus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983 , 56, 1282-7	5.6	24
26	Critical illness and low testosterone: effects of human serum on testosterone transport into rat brain and liver. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983 , 56, 710-4	5.6	17
25	Kinetics of transport and phosphorylation of 2-fluoro-2-deoxy-D-glucose in rat brain. <i>Journal of Neurochemistry</i> , 1983 , 40, 160-7	6	97
24	Increased blood-brain barrier transport of protein-bound anticonvulsant drugs in the newborn. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1983 , 3, 280-6	7.3	24
23	Transport of propranolol and lidocaine through the rat blood-brain barrier. Primary role of globulin-bound drug. <i>Journal of Clinical Investigation</i> , 1983 , 71, 900-8	15.9	90
22	Kinetics of neutral amino acid transport through the blood-brain barrier of the newborn rabbit. <i>Journal of Neurochemistry</i> , 1982 , 38, 955-62	6	60
21	Measurement of cerebral glucose utilization using washout after carotid injection in the rat. <i>Journal of Neurochemistry</i> , 1982 , 38, 1413-8	6	23
20	On "lumped constant" nomograms. <i>Journal of Neurochemistry</i> , 1982 , 39, 1774-6	6	2
19	Kinetics of regional blood-brain barrier transport and brain phosphorylation of glucose and 2-deoxyglucose the barbiturate-anesthetized rat. <i>Journal of Neurochemistry</i> , 1982 , 38, 560-8	6	96
18	Nomogram for 2-deoxyglucose lumped constant for rat brain cortex. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1982 , 2, 197-202	7.3	56
17	Transport of protein-bound hormones into tissues in vivo. <i>Endocrine Reviews</i> , 1981 , 2, 103-23	27.2	376
16	The interaction of transport and metabolism on brain glucose utilization: a reevaluation of the lumped constant. <i>Journal of Neurochemistry</i> , 1981 , 36, 1601-4	6	93
15	Enkephalin and blood-brain barrier: studies of binding and degradation in isolated brain microvessels. <i>Endocrinology</i> , 1981 , 109, 1138-43	4.8	92
14	Palmitate and cholesterol transport through the blood-brain barrier. <i>Journal of Neurochemistry</i> , 1980 , 34, 463-6	6	120
13	Transport of albumin-bound melatonin through the blood-brain barrier. <i>Journal of Neurochemistry</i> , 1980 , 34, 1761-3	6	87

12	Transport of thyroid and steroid hormones through the blood-brain barrier of the newborn rabbit: primary role of protein-bound hormone. <i>Endocrinology</i> , 1980 , 107, 1705-10	4.8	28
11	Effects of progesterone-binding globulin versus a progesterone antiserum on steroid hormone transport through the blood-brain barrier. <i>Endocrinology</i> , 1980 , 106, 1137-41	4.8	13
10	Influx of thyroid hormones into rat liver in vivo. Differential availability of thyroxine and triiodothyronine bound by plasma proteins. <i>Journal of Clinical Investigation</i> , 1980 , 66, 367-74	15.9	50
9	Kinetics of blood-brain barrier transport of pyruvate, lactate and glucose in suckling, weanling and adult rats. <i>Journal of Neurochemistry</i> , 1979 , 33, 439-45	6	250
8	Regional blood-brain barrier transport of the steroid hormones. <i>Journal of Neurochemistry</i> , 1979 , 33, 579-81	6	16
7	Carrier-mediated transport of thyroid hormones through the rat blood-brain barrier: primary role of albumin-bound hormone. <i>Endocrinology</i> , 1979 , 105, 605-12	4.8	141
6	Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. <i>Journal of Clinical Investigation</i> , 1979 , 64, 145-54	15.9	312
5	Glucose and amino acid metabolism in an established line of skeletal muscle cells. <i>Journal of Cellular Physiology</i> , 1978 , 96, 309-18	7	23
4	Transport of metabolic substrates through the blood-brain barrier. <i>Journal of Neurochemistry</i> , 1977 , 28, 5-12	6	486
3	Inorganic mercury: selective effects on blood-brain barrier transport systems. <i>Journal of Neurochemistry</i> , 1976 , 27, 333-5	6	24
2	Kinetics of blood-brain transport of hexoses. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1975 , 382, 377-92	3.8	211
1	Kinetic analysis of blood-brain barrier transport of amino acids. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1975 , 401, 128-36	3.8	263